Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

First anti-FcRn PoC study for the treatment of NMOSD Anti-FcRn antibody with potential to become a portfolio-in-a-product CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, April 21, 2020 /PRNewswire/ -- Harbour BioMed (HBM) today announced first patient dosing in a Phase 1b/2a...

from PR Newswire: https://ift.tt/2xOgYwi